Ophthalmic Consultants of Boston

Annexon, Inc. presents ANX007, a C1q inhibitor, at Floretina-ICOOR 2024, demonstrating vision protection and photoreceptor preservation in GA. Phase 3 ARCHER II trial actively enrolling, with data expected in 2026.

Oculis announces updates on the DIAMOND Phase 3 program with OCS-01 for DME, to be presented at Innovate Retina and Eyecelerator 2024. The program aims to assess the efficacy and safety of OCS-01 eye drops in DME at Week 52, with both DIAMOND-1 and DIAMOND-2 trials enrolling 350 patients each. Additionally, Oculis anticipates topline results from the ACUITY Phase 2 trial with OCS-05 for acute optic neuritis by the end of 2024.

Annexon presents ANX007 Phase 2 ARCHER trial data in geographic atrophy (GA) at Retina Society and Euretina Congress, demonstrating vision protection and photoreceptor preservation, with Phase 3 ARCHER II trial initiated.